Skip to main content

Table 3 Vaginal stenosis (CTCAE v3.0 scale) after 12 months (n = 142)

From: Topical estrogen, testosterone, and vaginal dilator in the prevention of vaginal stenosis after radiotherapy in women with cervical cancer: a randomized clinical trial

Vaginal stenosis after radiotherapy

Vaginal stenosis after 12 months

Total

p-value*

0

1

2

Testosterone

    

p < 0.01a

 0

1 (3.57%)

6 (21.43%)

2 (7.14%)

9 (32.14%)

 

 1

0 (0.00%)

10 (35.71%)

6 (21.43%)

16 (57.14%)

 2

0 (0.00%)

0 (0.00%)

3 (10.71%)

3 (10.71%)

Total

01 (3.57%)

16 (57.14%)

11 (39.29%)

28 (100.00%)

 

Estrogen

    

P < 0.01b

 0

1 (2.44%)

8 (19.51%)

0 (0.00%)

9 (21.95%)

 

 1

0 (0.00%)

20 (48.78%)

10 (24.39%)

30 (73.17%)

 2

0 (0.00%)

1 (2.44%)

1 (2.44%)

2 (4.88%)

Total

1 (2.44%)

29 (70.72%)

11 (26.83%)

41 (100.00%)

 

Vaginal dilator

    

p = 0.372c

 0

1 (3.70%)

2 (7.41%)

1 (3.70%)

4 (14.81%)

 

 1

1 (3.70%)

15 (55.56%)

4 (14.81%)

20 (74.07%)

 2

0 (0.00%)

1 (3.70%)

2 (7.41%)

3 (11.11%)

Total

2 (7.41%)

18 (66.67%)

7 (25.93%)

27 (100.00%)

 

Lubricant gel

    

P < 0.01d

 0

2 (4.35%)

7 (15.22%)

3 (6.52%)

12 (26.09%)

 

 1

0 (0.00%)

21 (45.65%)

9 (19.57%)

30 (65.22%)

 2

0 (0.00%)

3 (6.52%)

1 (2.17%)

4 (8.70%)

Total

2 (4.35%)

31 (67.39%)

13 (28.26%)

46 (100.00%)

 
  1. *Symmetry test a S = 14.00; GL = 3; b S = 15.36; GL = 3; c S = 3.13; GL = 3; d S = 13.00; GL = 3